BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Piaserico S, Messina F, Russo FP. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Am J Clin Dermatol 2019;20:829-45. [PMID: 31222626 DOI: 10.1007/s40257-019-00457-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Motolese A, Ceccarelli M, Macca L, Li Pomi F, Ingrasciotta Y, Nunnari G, Guarneri C. Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. Biomedicines 2022;10:228. [DOI: 10.3390/biomedicines10020228] [Reference Citation Analysis]
2 Glowacka P, Rudnicka L, Warszawik-Hendzel O, Sikora M, Goldust M, Gajda P, Stochmal A, Blicharz L, Rakowska A, Olszewska M. The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections. Biology (Basel) 2020;9:E192. [PMID: 32731331 DOI: 10.3390/biology9080192] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
3 Magrì S, Chessa L, Demurtas M, Cabras F, Mocci G. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. Eur J Gastroenterol Hepatol 2021;33:623-30. [PMID: 33470695 DOI: 10.1097/MEG.0000000000002076] [Reference Citation Analysis]
4 Lu J, Wang Y, Li Y, Gong Y, Ding Y, Shi Y, Algalil FA. Comparative Study on the Clinical Efficacy and Safety of Acitretin and MTX in the Treatment of Pustular Psoriasis by TLR7/MyD88/CXCL16 Pathway. Applied Bionics and Biomechanics 2022;2022:1-7. [DOI: 10.1155/2022/9640326] [Reference Citation Analysis]
5 De Simone C, Fargnoli MC, Amerio P, Bianchi L, Esposito M, Pirro F, Potenza C, Ricceri F, Rongioletti F, Stingeni L, Prignano F. Risk of infections in psoriasis: assessment and challenges in daily management. Expert Rev Clin Immunol 2021;17:1211-20. [PMID: 34696673 DOI: 10.1080/1744666X.2021.1997592] [Reference Citation Analysis]
6 Chularojanamontri L, Nimanong S, Wongpraparut C, Silpa-Archa N, Chaiyabutr C, Charoenpipatsin N. Impact of long-term systemic treatment for psoriasis on liver disease in psoriasis patients with coexisting hepatitis B virus infection. Dermatol Ther 2020;33:e14008. [PMID: 32654402 DOI: 10.1111/dth.14008] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Lambert JLW, Segaert S, Ghislain PD, Hillary T, Nikkels A, Willaert F, Lambert J, Speeckaert R. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2). J Eur Acad Dermatol Venereol 2020;34:1914-23. [PMID: 32791572 DOI: 10.1111/jdv.16683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
9 Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol 2020;16:207-28. [PMID: 31852268 DOI: 10.1080/1744666X.2019.1705785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
10 Liu Y, Cui SN, Duan MY, Dou ZL, Li YZ, Liu YX, Xia Y, Zhang JW, Yan XN, Han DR. Is there a relationship between psoriasis and hepatitis C? A meta-analysis and bioinformatics investigation. Virol J 2021;18:135. [PMID: 34215260 DOI: 10.1186/s12985-021-01606-z] [Reference Citation Analysis]
11 Megna M, Patruno C, Bongiorno MR, Gambardella A, Guarneri C, Romita P, Raimondo A, Loconsole F, Fabbrocini G. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection. Clin Drug Investig 2022. [PMID: 35633470 DOI: 10.1007/s40261-022-01163-5] [Reference Citation Analysis]
12 Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review. Am J Clin Dermatol 2021;22:425-42. [PMID: 33861409 DOI: 10.1007/s40257-021-00603-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
13 Kłujszo EH, Zarębska-Michaluk D, Kręcisz B, Witkowska A. Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infection. Dermatol Ther 2021;:e15274. [PMID: 34921578 DOI: 10.1111/dth.15274] [Reference Citation Analysis]